Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4131 Comments
1854 Likes
1
Dewel
Legendary User
2 hours ago
US stock customer concentration analysis and revenue diversification assessment for business risk evaluation. We identify companies with too much dependency on single customers or concentrated revenue sources.
š 284
Reply
2
Garwood
Consistent User
5 hours ago
Indices are trading within a defined range, emphasizing the importance of tactical entries and exits.
š 64
Reply
3
Ahnyah
Expert Member
1 day ago
Thorough analysis with clear explanations of key trends.
š 152
Reply
4
Sahrye
Experienced Member
1 day ago
This feels like I just unlocked confusion again.
š 289
Reply
5
Vesa
Power User
2 days ago
Free US stock ESG scoring and sustainability analysis for responsible investing considerations and long-term business sustainability evaluation. We evaluate environmental, social, and governance factors that increasingly impact long-term company performance and sustainability. We provide ESG scores, sustainability metrics, and impact analysis for comprehensive responsible investing support. Make responsible decisions with our comprehensive ESG analysis and sustainability scoring tools for sustainable portfolios.
š 168
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.